middle.news
OncoSil Medical Reports 44% Revenue Growth and FDA Approval in FY26
3:58pm on Friday 28th of August, 2026 AEST
•
Healthcare
Read Story
OncoSil Medical Reports 44% Revenue Growth and FDA Approval in FY26
3:58pm on Friday 28th of August, 2026 AEST
Key Points
43.9% revenue growth to $1.68 million
28.1% reduction in net loss to $10.86 million
FDA Humanitarian Device Exemption approval for distal cholangiocarcinoma
Australian TGA approval enables domestic commercial launch
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Oncosil Medical (ASX:OSL)
OPEN ARTICLE